Dyfrig A. Hughes researcher
Hughes, Dyfrig
VIAF ID: 121114561 (Personal)
Permalink: http://viaf.org/viaf/121114561
Preferred Forms
-
100 0 _ ‡a Dyfrig A. Hughes ‡c researcher
-
100 1 _ ‡a Hughes, Dyfrig
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better? |
![]() |
Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma |
![]() |
A Literature Review of GP Knowledge and Understanding of ME/CFS: A Report from the Socioeconomic Working Group of the European Network on ME/CFS (EUROMENE) |
![]() |
Managing access to advanced therapy medicinal products: Challenges for NHS Wales |
![]() |
Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease |
![]() |
Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi |
![]() |
Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma |
![]() |
Medication adherence-Key considerations for clinical pharmacologists |
![]() |
Medicines concordance and game theory |
![]() |
Multiple imputation of multiple multi-item scales when a full imputation model is infeasible |
![]() |
Nerve root block versus surgery |
![]() |
New advice on switching antiepileptic drugs might be a false economy. |
![]() |
The New and Non-Transparent Cancer Drugs Fund |
![]() |
New drugs for old: disinvestment and NICE |
![]() |
New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. |
![]() |
A new taxonomy for describing and defining adherence to medications |
![]() |
NICE and new: appraising innovation |
![]() |
NICE recommendations: why no disinvestment recommendations to offset investment decisions? |
![]() |
Non-compliance with antibiotic therapy for acute community infections: a global survey |
![]() |
Opportunity costs and local health service spending decisions: a qualitative study from Wales |
![]() |
Orphan drugs revisited: author's response |
![]() |
PAA4 ADVERSE DRUG REACTIONS IN ECONOMIC EVALUATIONS |
![]() |
Parenting programme for parents of children at risk of developing conduct disorder: cost effectiveness analysis |
![]() |
Patient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs |
![]() |
Patients' and healthcare professionals' views of cancer follow-up: systematic review |
![]() |
PCV100 INTERVENTIONS TO IMPROVE COMPLIANCE WITH LIPID LOWERING MEDICATIONS: A SYSTEMATIC REVIEW OF THE LITERATURE |
![]() |
PCV21 A BENEFIT-RISK ASSESSMENT OF USING CYP2C19 GENOTYPE INFORMATION TO GUIDE ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME |
![]() |
PGI2 BIOLOGICAL AGENTS FOR THE MANAGEMENT OF CROHN'S DISEASE IN ADULTS:A SYSTEMATIC REVIEW, META-ANALYSIS AND MULTIPLE TREATMENT COMPARISON |
![]() |
Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees. |
![]() |
Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery |
![]() |
PHP4 FACTORS INFLUENCING USER CHOICES TO VISIT EITHER GENERAL PRACTITIONERS OR COMMUNITY PHARMACISTS FOR MINOR AILMENTS—A DISCRETE CHOICE EXPERIMENT |
![]() ![]() |
PIN38 ASSESSING THE ASSOCIATION BETWEEN COMPLIANCE AND THERAPEUTIC FAILURE FOR ANTIRETROVIRAL DRUGS IN HIV POSITIVE PATIENTS |
![]() |
PMC21 FEASIBILITY, VALIDITY AND RELIABILITY OF THE WELSH VERSION OF THE EQ-5D HEALTH STATUS QUESTIONNAIRE |
![]() |
PMH52 COSTS OF NON-COMPLIANCE WITH ANTIPSYCHOTIC MEDICATIONS AMONG PATIENTS WITH SCHIZOPHRENIA |
![]() |
PMS49 TRENDS IN THE PRESCRIBING OF CONVENTIONAL ANTIRHEUMATIC THERAPY AMONG CANADIANS WITH RHEUMATOID ARTHRITIS: A RETROSPECTIVE COHORT STUDY |
![]() |
Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone |
![]() |
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors |
![]() |
POS5 LITERATURE REVIEW ON THE COSTS OF NON-COMPLIANCE IN OSTEOPOROSIS |
![]() |
Predicting adherence to medications using health psychology theories: a systematic review of 20 years of empirical research |
![]() |
Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modeling |
![]() |
Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey. |
![]() |
The problem of orphan drugs |
![]() |
Prof. John Urquhart |
![]() |
Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study |
![]() |
A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). |
![]() |
A randomised, patient-assessor blinded, sham-controlled trial of external non-invasive peripheral nerve stimulation for chronic neuropathic pain following peripheral nerve injury (EN-PENS trial): study protocol for a randomised controlled trial. |
![]() |
Rare disease prevention and treatment: the need for a level playing field. |
![]() |
Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group |
![]() |
Rationing of Drugs for Rare Diseases |
![]() |
Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. |
![]() |
Reply |
![]() |
Review of the use of resource use instruments based on patient recall in relation to other methods of resource use estimation |
![]() |
Ring-fencing a budget for cancer drugs: is it fair? |
![]() |
The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial |
![]() |
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial |
![]() |
Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia. |
![]() |
Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain |
![]() |
Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological Papers |
![]() |
Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections |
![]() |
Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. |
![]() |
A systematic review and empirical analysis of the relation between dose and duration of drug action |
![]() |
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives |
![]() |
A systematic review of economic evaluations of advanced therapy medicinal products |
![]() |
A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration |
![]() |
Systematic review: outcomes and adverse events from randomised trials in Crohn's disease |
![]() |
Taxonomy for methods of resource use measurement. |
![]() |
Trends and influences on use of antidiabetic drugs in England, 1992-2003. |
![]() |
The trials and tribulations of accessing data from routine sources. |
![]() |
Understanding medication compliance and persistence from an economics perspective. |
![]() |
Using discrete choice experiments to define patient preferences for outcomes in trials |
![]() |
Using routinely recorded data in a UK RCT: a comparison to standard prospective data collection methods |
![]() |
Using routinely recorded data in the UK to assess outcomes in a randomised controlled trial: The Trials of Access. |
![]() |
Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. |
![]() |
Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease |
![]() |
Value-based pricing: incentive for innovation or zero net benefit? |
![]() |
We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment |
![]() |
What influences persistence with medicines? A multinational discrete choice experiment of 2549 patients |
![]() |
What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics |
![]() |
When Drugs Don??t Work |
![]() |
প্রত্যুত্তর |
![]() |